Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
Clinical trial NCT03232567 · COMPLETED
Trial details
- NCT number
- NCT03232567
- Sponsor
- Altimmune, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-18
- Primary completion
- 2018-03-07
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.